Skip to main content
. Author manuscript; available in PMC: 2014 Sep 1.
Published in final edited form as: Autoimmunity. 2010 Mar;43(2):140–155. doi: 10.3109/08916930903229239

Figure 2.

Figure 2

CpG-ODN and GpG-ODN treatment modulates NZB/W mouse T lymphocyte responses ex vivo. Splenocytes from NZB/W mice were enriched for T lymphocytes at 32 weeks (left column) or 40 weeks (right column) of age. (A) T cells were stimulated with plate-bound anti-CD3 and anti-CD28 antibodies, and proliferation was assessed by thymidine incorporation assay after 48 h of culture. Experiment 1: *p < 0.05. Experiment 2: *p < 0.05; **p < 0.0001. (B) T cell cytokine production in response to ODN treatment. T cells were stimulated with plate-bound anti-CD3 plus anti-CD28, and levels of IFN-γ in culture supernatants were measured by ELISA after 48h. Experiment 1: NS, not significant (p = 0.062). Experiment 2: *p < 0.05. (C) Levels of IL-4 in culture supernatants were measured as in (B). Experiment 1: *p < 0.05. Experiment 2: *p < 0.05. Data are presented as mean + standard deviation (SD). p values were calculated using the Student’s t-test, and are based on comparison to results from the PBS-treated group.